Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
Roche's Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
01:05am, Monday, 20'th Oct 2025
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for peop
FDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis
01:00am, Monday, 20'th Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva�
FDA approves Roche's Gazyva/Gazyvaro for the treatment of lupus nephritis
01:00am, Monday, 20'th Oct 2025
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro®(obinutuzumab) for the treatment of adult pat
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA Breast Cancer study. Data s
Basel, 18 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus signi
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
04:20pm, Friday, 17'th Oct 2025
Basel, 17 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from two phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 and 1
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
04:20pm, Friday, 17'th Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety
CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for lupus nephritis
06:30am, Friday, 17'th Oct 2025
Basel, 17 October, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of
China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche
07:32pm, Thursday, 16'th Oct 2025
Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal cancer and other
BALA CYNWYD, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j
Roche to sell flu pill for $50 to cash-paying US patients
12:14pm, Thursday, 16'th Oct 2025
Roche on Thursday launched direct-to-consumer U.S. sales of its influenza antiviral pill Xofluza at a discounted cash price of $50, following similar moves by rivals as they scramble to address pressu
Genentech to sell flu pill directly to some consumers at a discount as Trump pressures drugmakers
12:08pm, Thursday, 16'th Oct 2025
Roche's Genentech said it will sell its flu pill, Xofluza, directly to certain patients at a discount in a bid to expand access to uninsured people, those with limited coverage or people whose plans d
Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch
11:45am, Thursday, 16'th Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the company's first Direct-to-Patient (DTP) program. This program, wh
Basel, 16 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented major updates on its innovative sequencing by expansion (SBX) technology at the American Society of Human Genetics (ASHG) 2025 Ann
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
09:41am, Wednesday, 15'th Oct 2025
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
